Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SPARC1316 in Healthy Volunteers and Asthma Patients
NCT02041221Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Jan 2014
- Primary completion
- Nov 2014
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SPARC1316 in asthma (6 arms), sponsored by Sun Pharma. Primary endpoint: Number of Subjects With Adverse Events at 2 weeks. Started Jan 2014; status: completed.
02
Drugs
SPARC1316
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02041221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041221.